ABSTRACT
The purpose of this study was to investigate the validity and reliability of the Korean version of a tool used to measure dental anxiety and fear. The Index of Dental Anxiety and Fear (IDAF-4C+) was translated into Korean, and modified and revised to adapt to Korean culture. A survey was conducted among 457 patients in a dental clinic. The validity and reliability were determined using PASW Statistics ver. 18.0 and IBM SPSS AMOS ver. 21.0. Factor analysis showed that Korean version of IDAF-4C+ was composed of three elements: dental anxiety, dental phobia, feared stimulus. The validity of the model was examined by confirmatory factor analysis and satisfied relevant requirements. All elements had convergent validity and discriminant validity exceeding requirements to ensure validity. Cronbach's α showed good reliability. In conclusion, the findings of this study demonstrate that the Korean version of IDAF-4C+ has high validity and reliability. Furthermore, it can be used in clinical practice and research to decrease dental anxiety and fear.
Subject(s)
Humans , Dental Anxiety , Dental Clinics , Reproducibility of ResultsABSTRACT
OBJECTIVES: This study analyzed the differences of body mass index(BMI) in Korean patients with Alzheimer's diseases(AD), Mild Cognitive Impairment(MCI), and healthy controls to verify whether low BMI is associated with cognitive impairment. Furthermore, this study also sought to examine any association between BMI and Mini Mental State Examination-Korean version(MMSE-K), Clinical Dementia Rating(CDR), and Global Deterioration Scale(GDS). METHODS: A total of 257 subjects were included in the study. History taking, mental status examination, physical examination and neurocognitive function test were carried out for the diagnosis of AD and MCI. The subjects' demographic data and presence of diseases were also surveyed. The overall cognitive function and severity of diseases were assessed using MMSE-K, GDS, and CDR. RESULTS: The order of BMI was found to be healthy controls>MCI>AD, with statistically significant differences among the groups. The order of MMSE-K scores was similar, with healthy controls>MCI>AD in statistically significant differences. The healthy controls had the lowest CDR and GDS scores, and AD patients had the highest scores. There was a significant positive correlation between BMI and MMSE scores(r=0.238, p=0.000). BMI was negatively correlated with CDR(r=−0.174, p=0.008) as well as with GDS(r=−0.233, p=0.000). CONCLUSIONS: Measuring BMI of patients with AD or MCI is expected to be meaningful in that BMI could be a clinical indicator of AD. We expect this to be beneficial for the diagnosis, prevention, and therapeutic approach of AD and also expect large-scale, long-term longitudinal studies to follow.
Subject(s)
Humans , Alzheimer Disease , Body Mass Index , Cognition Disorders , Cognition , Dementia , Diagnosis , Longitudinal Studies , Cognitive Dysfunction , Physical ExaminationABSTRACT
Impairment in spinal inhibition caused by quantitative alteration of GABAergic elements following peripheral nerve injury has been postulated to mediate neuropathic pain. In the present study, we tested whether neuropathic pain could be induced or reversed by pharmacologically modulating spinal GABAergic activity, and whether quantitative alteration of spinal GABAergic elements after peripheral nerve injury was related to the impairment of GABAergic inhibition or neuropathic pain. To these aims, we first analyzed the pain behaviors following the spinal administration of GABA antagonists (1 microgram bicuculline/rat and 5 microgram phaclofen/rat), agonists (1 microgram muscimol/rat and 0.5 microgram baclofen/rat) or GABA transporter (GAT) inhibitors (20 microgram NNC-711/rat and 1 microgram SNAP-5114/rat) into naive or neuropathic animals. Then, using Western blotting, PCR or immunohistochemistry, we compared the quantities of spinal GABA, its synthesizing enzymes (GAD65, 67) and its receptors (GABAA and GABAB) and transporters (GAT-1, and -3) between two groups of rats with different severity of neuropathic pain following partial injury of tail-innervating nerves; the allodynic and non-allodynic groups. Intrathecal administration of GABA antagonists markedly lowered tail-withdrawal threshold in naive animals, and GABA agonists or GAT inhibitors significantly attenuated neuropathic pain in nerve-injured animals. However, any quantitative changes in spinal GABAergic elements were not observed in both the allodynic and non-allodynic groups. These results suggest that although the impairment in spinal GABAergic inhibition may play a role in mediation of neuropathic pain, it is not accomplished by the quantitative change in spinal elements for GABAergic inhibition and therefore these elements are not related to the generation of neuropathic pain following peripheral nerve injury.
Subject(s)
Animals , Rats , Blotting, Western , GABA Agonists , GABA Antagonists , gamma-Aminobutyric Acid , Immunohistochemistry , Negotiating , Neuralgia , Peptides , Peripheral Nerve Injuries , Polymerase Chain ReactionABSTRACT
The Bcl-2 protein has been shown to block apoptosis induced by a variety of stimuli. We have performed the experiments which cell death can be blocked by the bcl-2 proto-oncogene under moderate(50-100mM) or high ethanol treatment(400-600mM). As a result of morphological changes, and MTT assay, cell death was blocked by Bcl-2 under 100mM ethanol. However, the results of DNA fragmentation and RT-PCR(ICE, and CPP32), immunoblotting(CPP32, and PARP) for SK-pcDNA3 cells(vector only) and SK-Bcl-2 cells(stably expressed bcl-2 gene) were showen to be no significant differences between two cell lines. These result suggested that cell death induced by ethanol was not followed by apoptosis mechanism, and was blocked by the bcl-2 proto-oncogene with moderate ethanol.